Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a Open-label Study of the Oral Farnesoid X Receptor (FXR) Modulator EYP001a to Assess Its Safety and Anti-viral Effect in Chronic Hepatitis B (CHB) Patients in Combination With Pegylated Interferon alpha2a (Peg-IFN) Alone and With Entecavir (ETV)

Next Previous
Search
Trial Profile

A Phase 2a Open-label Study of the Oral Farnesoid X Receptor (FXR) Modulator EYP001a to Assess Its Safety and Anti-viral Effect in Chronic Hepatitis B (CHB) Patients in Combination With Pegylated Interferon alpha2a (Peg-IFN) Alone and With Entecavir (ETV)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 26 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vonafexor (Primary) ; Entecavir; Peginterferon alfa-2a
  • Indications Hepatitis B
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors ENYO Pharma

    • Most Recent Events

    • 22 Aug 2022 Status changed from active, no longer recruiting to completed.
    • 30 Jul 2021 According to results presented in an ENYO Pharma media release, more detailed results from this study will be submitted for presentation at a scientific conference in Fall this year.
    • 30 Jul 2021 According to results presented in an ENYO Pharma media release, results from this study were presented at the recent EASL meeting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top